Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

2022100 citationsJournal Articlehybrid Open Access

Authors

Caicun Zhou · Tongji University

Dingzhi Huang · Tianjin Medical University Cancer Institute and Hospital

Yun Fan · University of Chinese Academy of Sciences

Xinmin Yu · Zhejiang Cancer Hospital

Yunpeng Liu · First Hospital of China Medical University

Yongqian Shu · Jiangsu Province Hospital

Zhiyong Ma

Abstract

Tislelizumab was found to have a significantly improved and long-term clinical benefit in OS versus docetaxel in pretreated patients with advanced NSCLC, regardless of PD-L1 expression.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Thoracic Oncology

Volume 18, Issue 1, pp. 93-105

DOI: 10.1016/j.jtho.2022.09.217

Field-Weighted Citation Impact: 9.52